{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:07:50Z","timestamp":1761743270177,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T00:00:00Z","timestamp":1250726400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1590\/s1807-59322009000800004","type":"journal-article","created":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T01:04:24Z","timestamp":1251335064000},"page":"731-734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib"],"prefix":"10.1016","volume":"64","author":[{"given":"Ana Carolina Costa","family":"Scerni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo Azevedo","family":"Alvares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cristina","family":"Beltr\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00ea Regina","family":"Bentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza Cristina","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra Quinto","family":"Bentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Alexandre Rodrigues","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1590\/S1807-59322009000800004_bib1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1590\/S1807-59322009000800004_bib2","first-page":"1217","article-title":"Reverse transcription\/polymerase chain reaction (RT\/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results","volume":"10","author":"Melo","year":"1996","journal-title":"Leukemia"},{"key":"10.1590\/S1807-59322009000800004_bib3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1590\/S1807-59322009000800004_bib4","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1073\/pnas.84.18.6558","article-title":"In vitro transformation of immature hematopoietic cells by the P210 BCR\/ABL oncogene product of the Philadelphia chromosome","volume":"84","author":"McLaughlin","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1590\/S1807-59322009000800004_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2013a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1590\/S1807-59322009000800004_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1590\/S1807-59322009000800004_bib7","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1590\/S1807-59322009000800004_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/beha.2001.0190","article-title":"Minimal residual disease in chronic myeloid leukaemia patients","volume":"15","author":"Hochhaus","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1590\/S1807-59322009000800004_bib9","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1590\/S1807-59322009000800004_bib10","first-page":"803","article-title":"Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia","volume":"4","author":"de Lemos","year":"2005","journal-title":"Genet Mol Res"},{"key":"10.1590\/S1807-59322009000800004_bib11","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1590\/S1807-59322009000800004_bib12","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of 'real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1590\/S1807-59322009000800004_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1590\/S1807-59322009000800004_bib14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1590\/S1807-59322009000800004_bib15","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/cncr.22498","article-title":"Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country","volume":"109","author":"Aziz","year":"2007","journal-title":"Cancer"},{"key":"10.1590\/S1807-59322009000800004_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1532\/IJH97.06157","article-title":"Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan","volume":"85","author":"Matsuo","year":"2007","journal-title":"Int J Hematol"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222025704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222025704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.scielo.br\/pdf\/clin\/v64n8\/a04v64n8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:14:21Z","timestamp":1761722061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222025704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1807593222025704"],"URL":"https:\/\/doi.org\/10.1590\/s1807-59322009000800004","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1590\/S1807-59322009000800004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}